0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Siponimod - Launch Insight, 2019
Published Date: February 2019
|
Report Code: DELV-Laun-34
Home | Market Reports | Business & Industrial | Pharmaceuticals & Biotech
Siponimod Launch Insight 2019

Siponimod - Launch Insight, 2019

Code: DELV-Laun-34
Report
February 2019
Pages:50
Delveinsight
Description
Table of Content
Tables & Figures

 

 

 

 

 

Report Scope

Report Attributes Report Details
Report Title Light Commercial Vehicle (LCV) Market Research Report
By Type Conventional engine vehicles, Alternative fuel vehicles
By Application Residential use, Commercial use, Industrial use
By Companies Ford Motor Company, Groupe PSA, Renault, Anhui Jianghuai Automobile, Ashok Leyland, Avtovaz, Toyota Motor, Gaz Group, General Motors, Honda Motor Company, Hyundai Motor Company, Isuzu Motors, Mitsubishi Motors, Opel, Paccar, Tata Motors
Regions Covered North America, Europe, APAC, Latin America, MEA
Base Year 2020
Historical Year 2018 to 2019 (Data from 2010 can be provided as per availability)
Forecast Year 2028
Number of Pages 104
Number of Tables & Figures 73
Customization Available Yes, the report can be customized as per your need.

 

 

 

 

 

 

 

DelveInsight’s, “Siponimod, Launch Insight, 2019” report provides comprehensive Insight about the Siponimod's launch. The report covers all the indications for which the Siponimod is being developed and also provides the competitive landscape for the major indications. The report further includes patent details, forecasted sales till 2022 and post launch market positioning.

The report will provide a clear picture of market positioning of the upcoming launch of Siponimod and will also provide the insight about how Siponimod will evolve in the market as well as within its respective class.Report provides detailed information of clinical trials that have been or are being conducted for this product. Analysis and Insightful information around the clinical trials is provided by assessment of the trial results.

Attribute analysis carried out by our analysts helps in understanding how the upcoming launch scores itself in comparison to other competitors (both marketed and pipeline). The scoring and analysis has been based upon scrutinizing data from all key clinical trials for the product. A head to head comparison with marketed products if available is scanned thoroughly. Further, analyzing data of other competitors with regards to the product also assists in proper scoring of the product in its space.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope

• Detailed product description including its chemical properties, molecule type and mechanism of action
• Detailed description of non-clinical and clinical studies for all the indications
• Patent expiry analysis of the drug along with other competitors in the market
• Forecasted sales till 2022
• Siponimod market positioning analysis
• Siponimod class share evolution

Report Introduction
Siponimod Overview
Siponimod of action
Pre-clinical Characterization
• Indication 1
• Indication 2
Clinical Characterization
• Indication 1
• Indication 2
Product Developmental Activities
• Collaboration
• Mergers & Acquisitions
• Financing
Siponimod Market Evolution
Siponimod Class Share Evolution
Siponimod Market Positioning
Patent Expiry Analysis
Competitive Landscape for the Siponimod in major indications
Appendix

List of Tables

Table 1: Siponimod, Heat Map
Table 2: Clinical Trial Landscape
Table 3: Clinical Efficacy Data from Cross Trials
Table 4: Competitive Landscape for Siponimod in Indication 1
Table 5: Competitive Landscape for Siponimod in Indication 2

List of Figures

Figure 1: Siponimod Developmental Milestones
Figure 2: Siponimod Sales Forecast till 2023
Figure 3: Siponimod Class Share Evolution
Figure 4: Comparative analysis of Siponimod with marketed products in the same class
Figure 5: Patent Expiry Analysis

SELECT A FORMAT
Added to Cart
Electronic (PDF)

$1500

This license allows only one user to access the PDF.
Electronic (PDF)

$3000

This license allows all the users of an enterprise residing in one location to access the PDF
Electronic (PDF)

$4500

This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
SecuX Technology Inc

RELATED REPORTS

Global Substrate Cutting Device Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-23Z18292
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Targeted Radionuclide Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-14Z15017
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Global Microfluidic Single-Cell Analysis and Screening System Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-7M18883
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Medicinal Liquid Filling Equipment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-37J14968
Thu Dec 12 00:00:00 UTC 2024

Add to Cart